Where can I find the protein concentration?

The protein concentration of each product is listed on the Certificate of Analysis. This value is determined for each individual lot and reflects the actual concentration (mg/mL) of the material you received.

Where can I find the recommended storage conditions?

Storage conditions are listed on both the product datasheet and the Certificate of Analysis. These recommendations are based on internal stability assessments and are intended to maintain protein integrity and activity.

Where can I find reconstitution instructions for lyophilized products?

If your product is supplied lyophilized, recommended reconstitution instructions are provided on the product datasheet. These instructions outline the suggested solvent and handling tips to ensure optimal recovery and stability.

How should I store my product after reconstitution?

Unless otherwise stated on the datasheet or COA, we recommend aliquoting reconstituted material and storing at –80 °C to avoid repeated freeze–thaw cycles, which may impact protein stability and activity.

Apolipoprotein CIII (Lyophilized)

Name: Apolipoprotein CIII (Lyophilized)
SKU: 16-16-120303-L-100UG
Availability: InStock

ApoCIII, ApoC3

A component of VLDL, chylomicrons, and HDL which inhibits lipoprotein lipase activation by displacing Apo CII. Elevated Apo CIII levels correlate with increased cardiovascular risk and type 2 diabetes.

Purity: ≥95% (SDS-PAGE)

Source: Human Plasma

Molecular Weight: 8.75 kDa

Form: Lyophilized

View All Specifications

Product Description

Role of protein in biology

Apolipoprotein CIII (ApoCIII) is a 79-amino acid glycoprotein primarily synthesized in the liver and intestine, circulating on triglyceride-rich lipoproteins (TRLs) such as VLDL, chylomicrons, and HDL. Functionally, ApoCIII inhibits lipoprotein lipase (LPL) activity by displacing its activator ApoCII, thereby reducing triglyceride hydrolysis and delaying hepatic clearance of TRLs via LDL receptor-related protein 1 (LRP1) and syndecan-1 pathways. It also promotes VLDL secretion under lipid-rich conditions, exacerbating hypertriglyceridemia. Clinically, elevated ApoCIII levels (>15 mg/dL) correlate with hypertriglyceridemia, atherosclerosis, and coronary heart disease, while loss-of-function variants reduce cardiovascular risk by 40%. ApoCIII overexpression induces insulin resistance by impairing skeletal muscle glucose uptake and pancreatic β-cell function, with elevated plasma levels predicting type 2 diabetes progression.

Common research uses

Therapeutically, ApoCIII is targeted using antisense oligonucleotides (e.g., volanesorsen), which lower triglycerides by 70–80% in familial chylomicronemia syndrome, and RARα agonists like AM580 that suppress hepatic ApoCIII synthesis via HNF4α downregulation. Synthetic ApoCII mimetics (C-II-a) counteract ApoCIII-mediated LPL inhibition 3, while dual APOC3/APOB gene silencing strategies show promise for combined dyslipidemias. Normal plasma concentrations (8–15 mg/dL) serve as biomarkers for cardiovascular risk stratification, particularly in diabetic populations. Emerging evidence positions ApoCIII inhibition as a dual therapeutic approach for metabolic and cardiovascular diseases.

Common uses include lipid metabolism studies, cardiovascular research.